Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Annovis (NYSE: ANVS) announced two presentations at AD/PD™ 2026 in Copenhagen, March 17-21, 2026, covering clinical data for buntanetap in Parkinson’s disease and an update on the pivotal Phase 3 trial in early Alzheimer’s disease.

Rhea-AI Summary

Annovis (NYSE: ANVS) announced two presentations at AD/PD™ 2026 in Copenhagen, March 17-21, 2026, covering clinical data for buntanetap in Parkinson’s disease and an update on the pivotal Phase 3 trial in early Alzheimer’s disease.

Presenters and session IDs: Presentation #3581 on PD cognition/biomarkers and Presentation #3582 on a 6- and 18-month randomized Phase 3 trial in early AD, both presented by Cheng Fang, Ph.D.

Argus Mar 3 session

-3.37% close to close Open Argus

Details

News Market Reaction – ANVS

On Mar 3, the day this news came out, ANVS closed 3.37% below the previous close.

Data tracked by StockTitan Argus for the Mar 3 session.

Key Figures

Number of presentations: 2 presentations Conference edition: 20th International Conference Conference dates: March 17-21, 2026 +4 more

Number of presentations

2 presentations

AD/PD™ 2026 conference

Conference edition

20th International Conference

AD/PD™ 2026

Conference dates

March 17-21, 2026

AD/PD™ 2026 in Copenhagen

Presentation ID

ID: 3581

PD cognition and MCI/mild dementia study

Presentation ID

ID: 3582

Early Alzheimer’s buntanetap Phase 3 trial

Trial duration

6-month

Symptomatic efficacy period in early AD trial

Trial duration

18-month

Longer-term disease-modifying period in early AD trial

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Alzheimer’s DSMB review

   24h Move

   +2.5%

   DSMB cleared pivotal Alzheimer’s Phase 3 to continue without safety changes.

2. Dec 18

   PD OLE study launch

   24h Move

   -0.5%

   Announced long-term open-label extension in Parkinson’s to expand buntanetap data.

3. Dec 16

   Corporate webinar notice

   24h Move

   +4.0%

   Scheduled January 2026 update webinar on programs and upcoming milestones.

4. Dec 03

   PD biomarker presentation

   24h Move

   +5.4%

   Presented Phase 3 PD biomarker and cognition data at Parkinson Study Group meeting.

5. Nov 24

   CTAD 2025 presentations

   24h Move

   +7.9%

   Announced CTAD talks on PD amyloid co-pathology and double 6/18‑month AD Phase 3.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, biomarker, α-Synucleinopathies, randomized, placebo-controlled, double-blind, +2 more

6 terms

phase 3 medical

"a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

biomarker medical

"focus on cognition and biomarker findings, and provide an update on the ongoing"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

α-Synucleinopathies medical

"Theme C: α-Synucleinopathies Presentation #1 (ID:3581) Title:"

α-synucleinopathies are a group of brain disorders caused by buildup of the protein alpha‑synuclein that damages nerve cells and leads to problems with movement, thinking and automatic body functions (like blood pressure or digestion). They matter to investors because they define a common biological target and market category for drugs and diagnostics: a successful therapy or test can create large commercial value, while failed trials or unclear diagnostic criteria can sharply affect company valuations — like rust in machinery that determines which repair tools will sell.

randomized, placebo-controlled, double-blind medical

"A Dual 6-month & 18-month Randomized, Placebo-Controlled, Double-Blind Clinical Trial"

A randomized, placebo-controlled, double-blind study is a clinical trial design where participants are assigned by chance (like flipping a coin) to receive either the experimental treatment or an inactive pill, and neither the participants nor the researchers know who got which until the study ends. Investors care because this setup reduces bias and chance effects, so positive results from such a trial carry much more credibility and lower the risk that promising early data will later fail.

β-Amyloid medical

"Theme A: β-Amyloid Diseases “We are proud to present the continued"

β-amyloid is a small protein fragment that can build up and clump together in the brain, forming sticky plaques linked to nerve cell damage and cognitive decline. Investors watch it because therapies or tests that reduce, clear, or measure these clumps can change the outlook for drug development, regulatory approval, and company valuation, similar to how solving a visible product defect can reshape a manufacturer's market prospects.

pivotal medical

"update on the ongoing pivotal Phase 3 trial in early AD."

Pivotal describes a test, event, or decision that is decisive for whether a product, idea, or plan moves forward—most often used for a late-stage clinical trial or a regulatory review whose result determines approval or rejection. Investors care because a positive outcome typically unlocks major value (like market access or sales), while a negative one can sharply reduce expected future revenue; think of it as the final exam that decides whether a project passes or fails.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark.

The presentations will highlight clinical data supporting buntanetap's treatment effect in PD with a particular focus on cognition and biomarker findings, and provide an update on the ongoing pivotal Phase 3 trial in early AD.

Details

Presentation #1 (ID:3581)

• Title: Buntanetap Treatment in Parkinson’s Disease Patients with MCI or Mild Dementia
• Presenter: Cheng Fang, Ph.D., Senior VP, Research & Development
• Theme C: α-Synucleinopathies
  
  

Presentation #2 (ID:3582)

• Title: A Dual 6-month & 18-month Randomized, Placebo-Controlled, Double-Blind Clinical Trial Investigating Efficacy and Safety of Buntanetap in Early Alzheimer’s Participants
• Presenter: Cheng Fang, Ph.D., Senior VP, Research & Development
• Theme A: β-Amyloid Diseases
  
  

“We are proud to present the continued progress in enrollment for our Alzheimer’s disease pivotal study, reflecting strong engagement from both investigators and patients,” commented Cheng Fang, Ph.D., Senior VP, Research & Development at Annovis. “Additionally, we will present the biomarker data from our Parkinson’s disease study that further support buntanetap’s therapeutic efficacy and mechanism of action.”

AD/PD™ 2026 is a leading international conference dedicated to neurodegenerative diseases, convening top medical and scientific experts to present novel findings that advance understanding of disease mechanisms and improve treatment strategies for conditions such as Alzheimer’s and Parkinson’s.

Additional information and presentation updates are available on the conference’s official website.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Annovis (ANVS) present at AD/PD 2026 on March 17-21, 2026?

Annovis will present two posters: one on buntanetap in PD and one on its Phase 3 early AD trial. According to the company, presentations detail PD cognition and biomarker findings and a dual 6- and 18-month randomized, placebo-controlled AD trial update.

Who is presenting Annovis data at AD/PD 2026 for ANVS?

Cheng Fang, Ph.D., Senior VP Research & Development, will present both Annovis sessions at AD/PD 2026. According to the company, Fang will cover PD biomarker/cognition data and the ongoing pivotal Phase 3 early AD trial.

What are the topics of Annovis presentations (IDs 3581 and 3582) at AD/PD 2026?

Presentation ID 3581 focuses on buntanetap treatment in PD patients with MCI or mild dementia; ID 3582 covers a dual 6- and 18-month randomized Phase 3 trial in early AD. According to the company, both include clinical and biomarker data.

How does the Annovis AD/PD 2026 news affect the ANVS clinical program timeline?

The announcement reports presentation of ongoing trial updates but gives no new timeline changes. According to the company, it highlights enrollment progress for the Alzheimer’s pivotal study and biomarker findings in Parkinson’s research.

Where and when can investors learn more about ANVS presentations at AD/PD 2026?

AD/PD 2026 runs March 17-21, 2026, in Copenhagen; conference materials and updates are available on the conference website. According to the company, additional presentation details and updates will be posted through conference channels.

What clinical evidence will Annovis (ANVS) highlight about buntanetap at AD/PD 2026?

Annovis will highlight clinical data supporting buntanetap’s treatment effect in PD, focusing on cognition and biomarkers, and provide an update on its Phase 3 early AD trial. According to the company, the data support therapeutic effect and mechanism of action.